In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...
Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
MyChesCo on MSN14h
FDA Approves Zepbound in Landmark Move to Battle Obstructive Sleep ApneaThe fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback